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Defining the connections among neurons is critical to our understanding of the structure
and function of the nervous system. Recombinant viruses engineered to transmit across
synapses provide a powerful approach for the dissection of neuronal circuitry in vivo. We
recently demonstrated that recombinant vesicular stomatitis virus (VSV) can be endowed
with anterograde or retrograde transsynaptic tracing ability by providing the virus with
different glycoproteins. Here we extend the characterization of the transmission and gene
expression of recombinant VSV (rVSV) with the rabies virus glycoprotein (RABV-G), and
provide examples of its activity relative to the anterograde transsynaptic tracer form of
rVSV. rVSV with RABV-G was found to drive strong expression of transgenes and to spread
rapidly from neuron to neuron in only a retrograde manner. Depending upon how the
RABV-G was delivered, VSV served as a polysynaptic or monosynaptic tracer, or was
able to define projections through axonal uptake and retrograde transport. In animals
co-infected with rVSV in its anterograde form, rVSV with RABV-G could be used to begin
to characterize the similarities and differences in connections to different areas. rVSV
with RABV-G provides a flexible, rapid, and versatile tracing tool that complements the
previously described VSV-based anterograde transsynaptic tracer.
Keywords: vesicular stomatitis virus, transsynaptic infection, rabies, retrograde transneuronal tracing, in vivo,
technology, polysynaptic
INTRODUCTION
Mapping neuronal connectivity in the central nervous system
(CNS) of even simple organisms is a difficult task. Recombinant
viruses engineered to trace synaptic connections and express
transgenes promise to enable higher-throughput mapping of con-
nections among neurons than other methods, e.g., serial recon-
struction from electron micrographs (Bock et al., 2011; Briggman
et al., 2011). The Pseudorabies (PRV) and Rabies viruses (RABV)
have been the best characterized and most utilized circuit tracing
viruses to date (Ugolini et al., 1989; Kelly and Strick, 2000). RABV
was recently modified by Wickersham and colleagues such that
it can travel across only one synapse, allowing for a straightfor-
ward definition of monosynaptic connections (Wickersham et al.,
2007b). This strategy permitted the first unambiguous identifica-
tion of retrogradely connected cells from an initially infected cell
(“starter cell”), without the need for electrophysiology. Moreover,
the starter cell could be defined through the expression of a
specific viral receptor that limited the initial infection.
Recently, we created an anterograde monosynaptic virus that
complements the previously available retrograde viral tracers
(Beier et al., 2011). Vesicular stomatitis virus (VSV), a virus
related to RABV, with its own glycoprotein (G) gene (VSV-G), or
with a G from the unrelated lymphocytic choriomeningitis virus
(LCMV-G), spreads in the anterograde direction across synapses.
VSV can be used as a polysynaptic tracer that spreads across
many synapses, owing to the fact that the normal, replication-
competent form of the virus does not cause serious diseases in
humans (Brandly and Hanson, 1957; Johnson et al., 1966; Brody
et al., 1967). Whether the virus is a monosynaptic or polysynap-
tic tracer is determined by the method of delivery of the G gene
(Figure 1A). Advantages of VSV are that it is well-characterized,
is relatively simple in comparison to PRV, and it rapidly grows
to high titer in tissue culture cells. It is also being developed as a
vaccine vector, often using a G of another virus as the immuno-
gen, as well as being developed as a cytocidal agent that will target
tumor cells in humans (Balachandran and Barber, 2000; Stojdl
et al., 2000, 2003).
Previous studies of the anatomical patterns of transmission,
as well as physiological recordings, have shown that the trans-
mission of VSV and RABV among neurons is via synapses (Kelly
and Strick, 2000; Wickersham et al., 2007b; Beier et al., 2011).
In addition, it has been shown that RABV, as well as lentiviruses
with RABV-G in their envelope, travel retrogradely from an injec-
tion site (Mazarakis et al., 2001; Wickersham et al., 2007a). We
hypothesized that providing a recombinant VSV (rVSV) with the
RABV-G would create a retrograde polysynaptic transsynaptic
tracer without the biosafety concerns inherent to RABV. Our ini-
tial characterization of rVSV with RABV-G showed that indeed
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FIGURE 1 | Synaptic tracing strategies using VSV. (A) Schematic
illustrating the strategies for polysynaptic or monosynaptic retrograde or
anterograde transsynaptic transmission of rVSV encoding GFP. The initially
infected cell is indicated by an asterisk. VSV encoding a glycoprotein (G)
within its genome can spread polysynaptically. The direction of the
spread depends on the identity of the glycoprotein. Infected neurons are
shown in green. In some cases, the initially infected starter cell can be
defined by the expression of an avian receptor, TVA (tagged with a red
fluorescent protein). The TVA-expressing neurons can then be specifically
infected by rVSVG with the EnvA/RABV-G (A/RG) glycoprotein
(Wickersham et al., 2007b) on the virion surface [rVSVG(A/RG)]. These
starter cells are then yellow, due to viral GFP and mCherry from
TVA-mCherry expression. For monosynaptic tracing, the G protein is
expressed in trans in the TVA-expressing cell, and thus complements
rVSVG to allow transmission in a specific direction. (B) Genomic
diagrams of rVSV vectors. All VSVs contain four essential proteins: N, P,
M, and L. Some viruses encode a G gene in their genome, which allows
them to spread polysynaptically. rVSV vectors typically encode a
transgene in the first position, while others carry an additional transgene
in the G position. (C) Morphological characterization of rVSV-infected
neurons in several locations within the mouse brain. (i,ii)
Caudate-putamen (CP) neurons at 4 dpi from an injection of the CP with
rVSV(VSV-G) viruses encoding (i) CFP or (ii) Korange. (iii) Labeled
neurons of the CA1 region of the hippocampus are shown at 5 dpi
following injection into the hippocampus of rVSV(VSV-G) encoding Venus.
(iv,v) Cortical pyramidal neurons are shown following injection into the
CP of rVSV(RABV-G) expressing (iv) GFP at 24 hpi, or (v) mCherry at
48 hpi. Inset in (iv) is a high magnification of the neuron in panel (iv),
highlighting labeling of dendritic spines. (vi) Multiple viruses can be
co-injected into the same animal. Here, individual rVSVG(VSV-G) viruses
encoding CFP, GFP, Venus, Korange, and mCherry were used to infect
the cortex. Scale bars = 50µm.
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it could be taken up as a retrograde tracer (Beier et al., 2011).
To determine if it could transmit among neurons following its
replication in neurons, and to further analyze the transmission
patterns of both the monosynaptic and polysynaptic forms of
rVSV with RABV-G, we made injections into several CNS and
peripheral locations. In addition, we performed co-infections of
rVSV with RABV-G and the anterograde form of rVSV in order
to exploit the differences in the directionality of transmission of
these two viruses in mapping circuits.
RESULTS
VSV CAN ENCODE A VARIETY OF TRANSGENES
Schematics of viruses created and used throughout this study
are shown in Figure 1. We created rVSV vector plasmids car-
rying different transgenes in either the first or fifth genomic
positions (Figure 1B). After rescuing each virus, we tested the
ability of each to express transgenes in different brain regions
through intracranial injections (Figure 1C). All rVSV vectors
drove robust fluorophore expression 1 or 2 days post-infection
(hpi) (Figure 1C) (van den Pol et al., 2009). In fact, by 12
hpi, labeling was sufficiently bright to image fine morphological
details, such as dendritic spines (Figure 1C,iv).
PHYSIOLOGY OF CELLS INFECTED WITH rVSV ENCODING RABV-G
To characterize the physiological properties of cells infected
with rVSV, we tested a replication-competent rVSV encod-
ing GFP, with RABV-G in the genome in place of VSV-G
[hereafter designated rVSV(RABV-G)]. van den Pol et al. reported
that hippocampal neurons infected with replication-incompetent
(G-deleted or “G”) rVSV were physiologically healthy at
12–14 hpi, but were less so by 1 day post-infection (dpi) (van
den Pol et al., 2009). Given the known toxicity of both VSV
and RABV-G (Coulon et al., 1982), we tested the physiol-
ogy of cortical pyramidal neurons in the motor cortex (M1)
infected with rVSV(RABV-G). Between 12 and 18 hpi, the mem-
brane capacitance, input resistance, resting membrane potential,
and current-to-action potential firing relationship were indistin-
guishable between infected and uninfected neurons (Figure 2).
However, by 2 dpi, electrophysiological properties were so abnor-
mal in the infected cortical pyramidal cells that physiological
measurements could not be made.
VSV EXPRESSES TRANSGENES RAPIDLY IN NEURONS
The speed and strength of the expression of transgenes encoded
by VSV depends upon the gene’s genomic position (van den Pol
et al., 2009; Beier et al., 2011). Genes in the first position are
expressed the most highly, with a decrease in the level of expres-
sion in positions more 3′ within the viral plus strand. When GFP
was inserted into the first position of VSV, GFP fluorescence was
first detectable at approximately 1 hpi in cultured cells (van den
Pol et al., 2009).
In order to quantify the relative expression of a fluorescent
protein in the first genomic position in neurons, rat hippocam-
pal slices were infected with a replication-incompetent rVSV
that expresses mCherry (rVSVG, Figures 1A,B). This was a
G virus which had the RABV-G supplied in trans during the
preparation of the virus stock [referred to as rVSVG(RABV-G)].
Average fluorescence intensity of the infected cells was mea-
sured every hour over the course of 18 h. By 4 hpi at 37◦C,
red fluorescence was clearly visible, and reached maximal levels
by approximately 14 hpi (N = 3, Figure 3). Similar results were
obtained with a virus encoding GFP in the first genomic position
rather than mCherry (i.e., Figure 1B) (N = 3).
rVSV(RABV-G) SPREADS TRANSSYNAPTICALLY IN THE RETROGRADE
DIRECTION
We previously demonstrated that rVSV(RABV-G) could be taken
up retrogradely by neurons (Beier et al., 2011), but these exper-
iments did not distinguish between direct axonal uptake of the
initial inoculum vs. retrograde transsynaptic transmission follow-
ing viral replication. To distinguish between these two mecha-
nisms and to extend the previous analyses, we conducted further
experiments in the mammalian visual system (Figures 4A–G).
As visual cortex area 1 (V1) does not receive direct projec-
tions from retinal ganglion cells (RGCs), but rather receives
secondary input from RGCs via the lateral geniculate nucleus
(LGN), infection of RGCs from injection of V1 would demon-
strate retrograde transmission from cells which supported at
least one round of viral replication. Following a V1 injection
with rVSV(RABV-G), GFP-positive RGCs were observed in the
retina by 3 dpi (N = 3; Figure 4G). Importantly, viral labeling
in the brain was restricted to primary and secondary projec-
tion areas, even at 7 dpi. These included the LGN (Figure 4D)
and the hypothalamus (Figure 4E), two areas known to project
directly to V1 (Kandel, 2000). Selective labeling was observed in
other areas, such as cortical areas surrounding V1 (Figure 4C),
which project directly to V1, and also in the superior collicu-
lus (SC) stratum griseum centrale, which projects to the LGN
(Figure 4F). Labeling was also observed in the nucleus basalis,
which projects to the cortex, as well as many components of
the basal ganglia circuit, which provide input to the thalamus
[such as the caudate-putamen (CP), globus pallidus (GP), and
the subthalamic nucleus (STn)]. The amygdala, which projects
to the hypothalamus, was also labeled. Consistent with a lack of
widespread viral transmission, animals did not exhibit signs of
disease at 7 dpi.
These data show that rVSV(RABV-G) can spread in a ret-
rograde direction from the injection site, but do not address
whether the virus can spread exclusively in the retrograde direc-
tion. Directional transsynaptic specificity can only be definitively
addressed using a unidirectional circuit. We therefore turned to
the primary motor cortex (M1) to CP connection, in which neu-
rons project from the cortex to the CP, but not in the other direc-
tion (Figure 4H) (Beier et al., 2011). Injections of rVSV(RABV-G)
into M1 should not label neurons in the CP if the virus can only
label cells across synapses in the retrograde direction. Indeed,
at 2 dpi, areas directly projecting to the injection site, includ-
ing the contralateral cortex, were labeled (Figure 4I). Only axons
from cortical cells were observed in the CP, with no GFP-labeled
cell bodies present in the CP (Figure 4J), consistent with lack
of anterograde transsynaptic spread. By 3 dpi, a small number
of medium spiny neurons (MSNs) in the CP were observed,
likely via secondary spread from initially infected thalamic or GP
neurons (data not shown).
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FIGURE 2 | Physiological characterization of rVSV-infected and
uninfected layer 5 cortical pyramidal neurons following injection of
rVSV(RABV-G) into the CP. Slices were cut 12 hpi and recordings were
taken over the subsequent 6 h. (A) Example spike trains driven by 100,
200, and 400 pA square current pulses lasting 1 s for infected (left) and
uninfected (right) neurons. (B) A summary plot showing current/action
potential firing frequency relationships are unaffected by infection
(infected cells, N = 7; uninfected cells, N = 6). Horizontal bars denote
averages. Infection does not alter the (C) input resistance, the (D)
capacitance, or (E) resting membrane voltages (infected cells, N = 10,
uninfected cells, N = 9). Horizontal bars denote mean with standard
error of the mean.
PERIPHERAL UPTAKE OF rVSV(RABV-G) AND TRANSMISSION TO
THE CNS
A particular advantage of retrograde viral tracers is the ability to
label CNS neurons projecting to peripheral sites. This has been
a powerful application of both RABV and PRV (Ugolini et al.,
1989; Standish et al., 1994). To test if rVSV(RABV-G) could also
perform this function, we examined the innervation of the dura
surface by neurons of the trigeminal ganglion, a neuronal cir-
cuit thought to be involved in migraine headaches (Penfield and
McNaughton, 1940; Mayberg et al., 1984). These neurons have
axons, but not canonical dendrites, and send projections into the
spinal cord and brainstem. Therefore, the only way trigeminal
neurons could become labeled from viral application to the dura
is through retrograde uptake of the virus.
We applied rVSV(RABV-G) to the intact dura mater and
analyzed the dura, trigeminal ganglion, and CNS for label-
ing (Figure 4K). At the earliest time point examined, 3 dpi, we
observed axons traveling along the dura, but little other evidence
of infection (Figure 4L). No labeled neuronal cell bodies on the
dura were observed, consistent with the lack of neurons on this
surface. In contrast, we did find labeled cell bodies in the trigemi-
nal ganglion (Figure 4M). No infection was seen in the CNS, even
at 4 dpi, consistent with the lack of inputs from the brain into the
trigeminal ganglion (N = 4 animals).
THE KINETICS OF RETROGRADE TRANSSYNAPTIC SPREAD
To further characterize patterns and kinetics of viral transmis-
sion and directional specificity of transsynaptic spread, injections
of rVSV(RABV-G) were made into the CP (Figure 5A). In order
to determine which cells were labeled by direct uptake of virus
in the inoculum, a separate set of animals were injected into the
CP with the replication-incompetent rVSVG(RABV-G) (N = 3
animals, analyzed 3 dpi). Cells labeled by rVSVG(RABV-G)
were observed in the CP, GP, substantia nigra (SN), thalamus, and
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FIGURE 3 | Quantification of viral transgene expression over time.
(A) After 7 days in vitro (DIV), hippocampal slice cultures were infected with
rVSVG(RABV-G) expressing mCherry in the first genomic position. Sample
images of the same visual field are shown over time. (B) Fluorescence was
quantified as a function of time and was normalized to expression at 18 hpi.
The plot indicates averages ±1 SD, N = 3.
layers 3 and 5 of the cortex, consistent with infection at the axon
terminal and retrograde labeling of cell bodies of neurons known
to project directly to the CP (Figure 5C) (Albin et al., 1995). Areas
labeled by CP injection are indicated in Figure 5B.
The patterns of spread for the replication-competent
rVSV(RABV-G) were characterized over the course of 1–5 dpi
(Figures 5D–H). During this interval, progressively more cells
in infected regions were labeled by rVSV(RABV-G), includ-
ing within the CP, nucleus basalis, cortex, and GP (listed in
Figure 5B). In addition, more cortical cells were labeled in
clusters near cortical pyramidal neurons, both ipsilateral and
contralateral to the injected side, including neurogliaform
cells (data not shown). These data are in contrast to those
observed following infection with an anterograde transsynaptic
tracing virus, such as rVSV with its own G gene, rVSV(VSV-G)
(Figure 5B). At 3 dpi following rVSV(VSV-G) injection into the
CP, the cerebral cortex was not labeled, but regions receiving
projections from the CP, such as the STn, GP, and SN, were
labeled (Beier et al., 2011).
In order to investigate other areas for evidence of cell-to-cell
retrograde transsynaptic spread, the nucleus basalis was exam-
ined following infection of the CP with replication-competent
rVSV(RABV-G). The nucleus basalis was labeled by 2 dpi
(Figures 5E–H), consistent with at least a single transsynap-
tic jump, as this area does not directly project to the CP. The
virus appeared to travel transsynaptically at the rate of roughly
1 synapse per day, as evidenced by the lack of labeled neurogli-
aform cells in the cortex, and lack of neurons in the nucleus basalis
at 1 dpi, and label appearing in these cell types/areas at 2 dpi,
as previously observed (Beier et al., 2011). Labeling remained
well-restricted to the expected corticostriatal circuits at 5 dpi,
suggesting that viral spread becomes less efficient after cross-
ing one or two connections, consistent with injections into V1
(Figure 4). While glial cells can be infected and were observed
near the injection site (van den Pol et al., 2002; Chauhan et al.,
2010), infected glial cells away from the injection site generally
were not observed.
POLYSYNAPTIC TRACERS CAN BE COMBINED in vivo
One advantage of having both anterograde and retrograde forms
of the same virus is that they can be used in parallel, or in tandem,
to trace circuitry to and from a single or multiple sites of injec-
tion, with each virus having similar kinetics of spread and gene
expression. In fact, if different fluorophores are used in different
viruses, e.g., rVSV(VSV-G) and rVSV(RABV-G), then the viruses
can be co-injected into the same site and their transmission can be
traced independently (Figure 6A). This is most straightforward if
there are no cells at the injection site that are initially infected
by both viruses. Co-infected cells can be easily detected, as they
would express both fluorescent proteins shortly after injection.
In order to determine whether two viruses would allow simul-
taneous anterograde and retrograde transsynaptic tracing from
a single injection site, a rVSV(VSV-G) expressing Venus and a
rVSV(RABV-G) expressing mCherry were injected individually
(Figures 6B–D) or co-injected (Figures 6E–G) into the motor
cortex, and brains were examined 3 dpi. The pattern of label-
ing from the co-injected brains was equivalent to the patterns
observed when each virus was injected individually: rVSV(VSV-
G) was observed to infect neurons in the cortex, CP, and down-
stream nuclei, whereas the rVSV(RABV-G) was not observed to
infect neurons in the CP, but rather in the thalamus and nucleus
basalis (N = 4). The initial co-infection rate is dependent upon
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FIGURE 4 | rVSV(RABV-G) exhibits polysynaptic retrograde spread
in vivo. (A) Schematics of two parasaggital sections separated by 1.3mm
are shown. rVSV(RABV-G) injected into V1 (black needle) should yield
infected cells in the labeled areas shown in green, including RGCs in the
retina (panel ii). Areas projecting directly to V1, such as the hypothalamus
(h), LGN, as well as other cortical areas, can be labeled by direct
retrograde uptake of injected virions, whereas RGCs, which project to the
LGN, can only be labeled by secondary viral spread. (B) rVSV(RABV-G) was
injected into V1 (yellow arrowhead), and both the brain and retina
examined 7dpi. Infection in the brain appeared to be primarily in directly
projecting areas, including the surrounding cortices, the LGN (white arrow),
and hypothalamus (white arrowhead). Higher magnifications of labeled
cells from a V1 injection are shown in panels (C–G). (C) somatosensory
cortex, 7 dpi; (D) LGN, 3 dpi; (E) hypothalamus, 3 dpi; (F) SC, 3 dpi; (G)
RGC, 3 dpi. (H) Schematic of a coronal section showing rVSV(RABV-G)
injected into M1 (black needle). The contralateral cortex (green) should be
labeled by this virus, while at early time points such as 2 dpi, the CP,
which receives projections from the cortex but does not itself send
projections to the cortex, should not (gray). (I) Coronal section showing
GFP-labeled neurons in M1, imaged 4dpi. The injection site was in M1,
indicated by a yellow arrowhead, with neurons projecting to the injection
site indicated by the white arrowhead. (J) CP neuronal cell bodies were
not labeled, but labeled cortical axon bundles running through the CP were
observed (inset shows axon bundles in the area demarcated by the white
arrowhead). (K–M) rVSV(RABV-G) can trace circuits into the CNS from a
peripheral site. (K) Parasaggital schematic showing a predicted area of
infection following infection of the dura with a retrogradely transported
virus. rVSV(RABV-G) was applied to the intact dura (arrow) and if
retrograde uptake and transport can occur, trigeminal ganglion neurons that
project to the dura (green) should become labeled. (L) Examples of axons
located on the dura, 3 dpi. Infected neuronal cell bodies were not located
on the dura, (M) but instead were observed in the trigeminal ganglion. No
infection of the brain was observed in these animals. Scale bars: (B,I,J) =
1mm, (L) = 100µm, (C–G,M) = 50µm.
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FIGURE 5 | Time course of rVSV(RABV-G) spread from the CP
recapitulates the connectivity of known basal ganglia-thalamo-cortical
circuits. (A) A parasaggital schematic showing the relevant projections into
and from the injection site in the CP. Black needle points to injection site,
green = primary projecting regions, blue = secondary projecting region. CP,
caudate-putamen; GP, globus pallidus; SN, substantia nigra; STh, subthalamic
nucleus; Th, thalamus; NB, nucleus basalis. (B) Assessment of viral spread
from rVSV(RABV-G) and rVSV(VSV-G) injections into the CP. The presence or
absence of labeling is indicated by (+) and (−), respectively. The extent of
labeling is indicated by the number of (+). Some animals were infected with
G viruses to determine which areas were labeled by direct uptake of the
virions, rather than by replication and transmission. These were sacrificed at
3 dpi. (C) Parasaggital section of a brain infected with VSV[greek
delta]G(RABV-G). The injection site is marked by a red arrow. Several areas
that project directly to the CP were labeled due to direct uptake of the
virions, including the cortex, thalamus, and GP (arrowheads), 3 dpi. (D–H)
Replication-competent rVSV(RABV-G) was injected into the CP (red arrows),
and the time course of labeling was monitored for 5 days [(D) 1 day, (E) 2,
(F) 3, (G) 4, and (H) 5 days]. Insets show high magnifications of areas
indicated by white arrows. Sections from animals at 1 dpi show labeling
consistent with the initial infection [compare to rVSVG(RABV-G), panel C],
while spread to secondarily connected areas, such as the nucleus basalis,
was observed at 2 dpi (yellow arrows). Viral spread was relatively restricted to
the basal ganglia circuit, even out to 5 dpi. Scale bars = 1mm.
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FIGURE 6 | Simultaneous anterograde and retrograde transsynaptic
circuit tracing using rVSV. (A) Connectivity schematics of parasaggital
sections indicating patterns of spread from injection of M1 (injection needles)
with a polysynaptic virus transmitting across synapses in the (i) anterograde
or (ii) retrograde directions. Panel (iii) shows the pattern from co-injection of
two polysynaptic viruses, one anterograde and one retrograde. Green
represents the anterograde virus, red the retrograde virus, and yellow, both.
Note that yellow indicates that the area is predicted to host infection by both
viruses, with potentially some individual cells showing infection with both
viruses. (B) The anterograde transsynaptic virus rVSV(VSV-G), when injected
alone, labeled M1 as well as anterograde projection areas, such as the CP, GP,
and thalamus, whereas (C) the retrograde virus rVSV(RABV-G) labeled M1 as
well as areas projecting to the cortex, including the thalamus. (D) High
magnification of thalamic cells shown in (C) (white arrow). (E,F) Examples
taken from a series of parasaggital sections from the same brain of an animal
injected with both viruses simultaneously into M1. Co-infection of cells in M1
was not observed, (G), and no spurious labeling of anterograde or retrograde
projection regions was observed—i.e., the combination of viruses was equal
to the sum of each virus injected individually. Insets show high magnifications
of thalamic neurons in (E) and (F) labeled by the two viruses (indicated by the
yellow arrows) demonstrating no co-labeling. (G) A high magnification view
of the injection site in the cortex shown in panel (F) (white arrow), showing
independent labeling of neurons by each virus. (H) A schematic of a
parasaggital section depicting the pattern of transmission of an anterograde
(green) and retrograde (red) virus injected into two different areas of the basal
ganglia circuit. This strategy can be used to connect multiple elements in a
circuit. The rVSV(VSV-G) that expressed Venus (labeled cells depicted in
green) was injected into M1, while the rVSV(RABV-G) that expressed
mCherry was injected into the SN, where it labeled direct pathway MSNs in
the CP (yellow). (I) Using these coordinates, largely non-overlapping regions
of the CP were labeled by these viruses, as shown in (J). Scale bars:
(B,C,E,F,I) = 1mm; (D,G,J) = 50µm.
the dose of the initial inocula.When injecting 3 × 103 focus form-
ing units (ffu) rVSV(VSV-G) and 3 × 104 ffu rVSV(RABV-G), no
co-infection was observed at the injection site. Thus, co-infection
of the same brain region, without co-infection of the same cells,
does not alter the spreading behavior of either rVSV(VSV-G) or
rVSV(RABV-G).
One example of how this dual retrograde and anterograde
transsynaptic tracing system can be used is to determine if three
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distinct regions are connected and the directionality of any con-
nections. For example, the anterograde transsynaptic virus can be
injected into one region, the retrograde into another, and a third
region can then be examined for evidence of labeling by either or
both viruses (e.g., Figure 6H). To test this possibility, rVSV(VSV-
G) was injected into the motor cortex, rVSV(RABV-G) was
injected into the substantia nigra pars reticulara (SNr), and ani-
mals were sacrificed at 3 dpi. We observed that cells were singly
labeled, either with Venus [rVSV(VSV-G)] or with mCherry
[rVSV(RABV-G)], and were located largely in different regions
of the CP (Figures 6I,J) (N = 3). These results suggest that the
anterograde connections from the cells infected with rVSV(VSV-
G) in the M1 were with CP MSNs that did not project to the
region of the SNr injected with rVSV(RABV-G) (N = 3 animals).
VSV CAN TRACE MONOSYNAPTICALLY CONNECTED CIRCUITS IN THE
RETROGRADE DIRECTION
In addition to polysynaptic tracing, VSV can be modified to trace
circuits monosynaptically (Beier et al., 2011). With RABV, this
was achieved in vivo by first infecting with an adeno-associated
virus (AAV) expressing TVA, a receptor for an avian retrovirus,
and RABV-G (Wall et al., 2010). This was followed 3 weeks later by
infection with a G RABV with an EnvA/RABV-G chimeric gly-
coprotein on the virion surface (Wickersham et al., 2007b), which
allowed infection specifically of the cells expressing TVA. A sim-
ilar strategy was used to test rVSV’s ability to monosynaptically
trace retrogradely connected neurons in vivo. Inputs to choline
acetyltransferase (ChAT)-expressing neurons in the striatumwere
used for this test. These neurons primarily receive input from the
cortex and the thalamus (Thomas et al., 2000; Bloomfield et al.,
2007) (Figure 7A). In order to mark this population, we crossed
ChAT-Cre mice to Ai9 mice, which express tdTomato in cells
with a Cre expression history (Madisen et al., 2010). Six-week-old
mice from this cross were injected in the CP with two AAV vec-
tors: one expressing a Cre-conditional (“floxed”) TVA-mCherry
fusion protein, and another expressing a floxed RABV-G. Two
weeks later, the mice were injected in the same coordinates with
rVSVG with the EnvA/RABV-G chimeric glycoprotein on the
virion surface [rVSVG(A/RG)] (Beier et al., 2011). Cells suc-
cessfully infected with these two AAV vectors could host infection
by a rVSV and should be able to produce rVSV virions with
RABV-G on the surface. Such starter cells should also express
tdTomato and GFP. If rVSV were to be produced, and if it were
to transmit across the synapse retrogradely, cortical and thalamic
neurons should be labeled by GFP.
Mice injected with these AAV and rVSV viruses were sacrificed
5 days after rVSV infection, and brains analyzed for fluorescence.
As expected for starter cells, some neurons in the CP expressed
both tdTomato and GFP (Figure 7B). Outside of the CP, small
numbers of GFP+ neurons that were not mCherry+ were
observed in the cortex (Figures 7C,D) and thalamus (Figure 7E),
consistent with retrograde spread. Control animals not express-
ing Cre, or not injected with AAV encoding RABV-G, did not
label cells in the cortex or thalamus (N = 3 for both controls and
experimental condition).
DISCUSSION
rVSV(RABV-G) IS A RETROGRADE TRACER IN THE CNS
Here, we report on the use of rVSV as a retrograde transsynap-
tic tracer for CNS circuitry. VSV can be modified to encode the
RABV-G protein in the viral genome, allowing the virus to repli-
cate and transmit across multiple synaptically connected cells,
i.e., as a polysynaptic tracer. Alternatively, if the virus has the G
gene deleted from its genome and RABV-G is provided in trans,
FIGURE 7 | Monosynaptic retrograde tracing using rVSV in vivo.
(A) A schematic of a parasaggital section showing the predicted pattern of
monosynaptic retrograde spread from Choline Acetyltransferase
(ChAT)-expressing neurons in the CP to directly connected cells. A
combination of two Cre-dependent adeno-associated viruses (AAVs), one
expressing a TVA-mCherry fusion protein and the other RABV-G, were
injected into the CP of ChAT-Cre/Ai9 animals. This permits expression of the
transgenes encoded in the AAVs in cells with a ChAT expression history.
Two weeks later, rVSVG(A/RG), a G-deleted virus that only infects
TVA-expressing neurons, was injected into the same region, and the brain
was observed 5 days later. The injection of rVSV into the CP (black needle)
should result in infection of TVA-expressing neurons in the CP. From these
starter cells, monosynaptic spread could occur only to directly connected
inputs such as those in the cortex and thalamus (green). (B,B′ ) Initially
infected cells in the CP were both red (TVA-expressing) and green (rVSV
infected) (arrow). B′ shows the red and blue channels only, blue = DAPI.
(C–E) Examples of rVSV-infected cells in the cortex (C,E) and thalamus
(D) that were infected by monosynaptic transmission from the starter cells,
(arrows indicate cells infected by transmission), N = 3. Scale bars: (B,D) =
50µm, (C,E) = 500µm.
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it behaves as a monosynaptic tracer (Beier et al., 2011). Although
it has been known for many years that RABV travels retrogradely
among neurons (Astic et al., 1993; Ugolini, 1995; Kelly and Strick,
2003), and pseudotyping lentiviruses with RABV-G is sufficient
for axonal transport (Mazarakis et al., 2001), the retrograde trans-
mission specificity among neurons had not been clearly shown to
be a property of the G protein itself, as it might have been due
to other viral proteins in addition to, or instead of, the viral G
protein. Since native VSV does not have these retrograde transsy-
naptic properties (van den Pol et al., 2002; Beier et al., 2011),
and the only alteration to the VSV genome was the substitution
of the VSV G gene with the G gene of RABV, it is clear that the
RABV glycoprotein is responsible for retrograde direction of viral
transmission across synapses, at least in the case of rVSV.
VSV AS A VIRAL VECTOR FOR THE CNS: RAPID GENE EXPRESSION AND
GENOME CAPACITY
The early onset of gene expression from VSV relative to RABV
(one hour vs. multiple hours) makes it beneficial in experimen-
tal paradigms in which the experiment needs to be done within
a narrow window of time, such as tissue slices and explants. In
addition, more than one transgene can be encoded in the viral
genome without the need of a 2A or IRES element. The use of the
first position of the genome enhances the expression level of the
transgene inserted at that location, since VSV (and RABV) express
genes in a transcriptional gradient; therefore, the first gene is the
most highly transcribed (Knipe, 2007). This leads to rational pre-
dictions of expression levels so that one can choose the position of
insertion of a transgene, or transgenes, according to this gradient
and the desired level of expression. The size of the viral capsid is
apparently not rigid, allowing for the inclusion of genomes that
are substantially larger than the native genome, unlike the rigid
capacity for some other viral vectors, such as AAV (Duan et al.,
2000; Yan et al., 2000).
SUFFICIENCY OF GLYCOPROTEINS TO CONFER DIRECTIONALITY OF
rVSV SPREAD ENABLES NOVEL APPLICATIONS
The fact that VSV can be made to spread anterogradely (Beier
et al., 2011) or retrogradely across synapses with the change of
a single gene affords several advantages over viral tracers that
heretofore have not shown such flexibility in the directionality of
tracing. In addition to the obvious application of tracing antero-
grade connections, combinations can be made to exploit the
different forms of the virus. One example that employs the simul-
taneous infection with an anterograde and retrograde form of
VSV is demonstrated in Figure 6. This experiment was designed
to address whether the anterograde projections from the cortex
to the CP would label the same brain regions as were labeled by a
retrograde virus injected into the SN. Although a block of super-
infection by the virus may preclude infection of the same cell
with multiple rVSVs, adjacent cells could still become labeled by
different viruses (Whitaker-Dowling et al., 1983). The observed
results could be due to a preferential labeling by the anterograde
transsynaptic virus of indirect pathway MSNs in this experiment,
which then synapse onto the GP, thereby reflecting a viral bias.
Alternatively, it could indicate that the cortical neurons in the
injected region largely do not label the MSNs that project to the
area of the SN injected with the retrograde virus. One further
possibility is that too little virus was used to observe co-labeling
of a given region. However, given the density of infection (i.e.,
Figures 6I,J), the latter possibility seems unlikely. Additionally,
the spread of the polysynaptic rVSV(RABV-G) appears to atten-
uate with increasing numbers of synapses crossed, permitting an
analysis of more restricted viral spread. This is quite fortuitous, as
if spread were to continue, it would lead to widespread infection
and lethality. In addition, reconstruction of connectivity would be
more difficult. This reduced efficiency appears to also hold for the
monosynaptic form of VSV complemented with RABV-G, as the
efficiency of transmission appeared lower than the comparable
experiment with RABV (Watabe-Uchida et al., 2012). This is likely
due to viral attenuation when VSV-G is replaced with RABV-G.
ADVANTAGES OF VSV OVER OTHER VIRAL TRACERS: SAFETY
Wewere attracted to the use of VSV as a viral tracer due to its long
track record as a safe, replication-competent laboratory agent.
Laboratory workers using VSV have not contracted any diseases,
and natural VSV infections among human populations in Central
America and the southwestern United States (Rodríguez, 2002)
occur without evident pathology (Johnson et al., 1966; Brody
et al., 1967). VSV was thus an attractive candidate for its use as
a polysynaptic tracer for CNS studies, which requires an ability to
replicate through multiple transmission cycles. Both replication-
competent and incompetent forms of VSV are in use under
Biosafety Level 2 containment. Replication-competent RABV is
Biosafety Level 3, due to the fact that infection with replication-
competent RABV is almost always fatal to humans and in mice
when infected intracerebrally (Smith, 1981; Knipe, 2007).
Differences in pathogenicity between VSV and RABV are likely
due to the ability of RABV to evade the innate immune sys-
tem, particularly interferon (Hangartner et al., 2006; Junt et al.,
2007; Lyles and Rupprecht, 2007; Rieder and Conzelmann, 2009;
Iannacone et al., 2010). VSV infection efficiently triggers an inter-
feron response, and it has not evolved a method of escape from
this response, unlike RABV (Brzózka et al., 2006). In fact, VSV
is being pursued as a vaccine for other viruses, including RABV
(Lichty et al., 2004; Publicover et al., 2004; Kapadia et al., 2005;
Schwartz et al., 2007; Iyer et al., 2009; Geisbert and Feldmann,
2011). VSV does not typically spread beyond the initially infected
site in the periphery (Kramer et al., 1983; Vogel and Fertsch,
1987). This likely is the cause of the minor or absent symptoms in
humans and animals infected in nature. Polysynaptic VSV vectors
are thus predicted to be much safer than polysynaptic RABV vec-
tors. We have tested this prediction by injecting a series of mice in
the footpads and hind leg muscles with rVSV(RABV-G), with the
result that no injected animals showed any evidence of morbidity
or mortality (Beier, Goz et al., in preparation).
While safer for laboratory workers than RABV, the main draw-
back to using VSV is its rapid cellular toxicity (van den Pol et al.,
2009; Beier et al., 2011). Toxicity is due to suppression of cellu-
lar transcription and a block in the export of cellular RNAs from
the nucleus to the cytoplasm (Black and Lyles, 1992; Her et al.,
1997; Ahmed and Lyles, 1998; Petersen et al., 2000; von Kobbe
et al., 2000), as well as inhibition of the translation of cellular
mRNAs (Francoeur et al., 1987; Jayakar et al., 2000; Kopecky et al.,
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2001). VSV is much quicker to enact its gene expression pro-
gram than is RABV, such that cells suffer the toxic effects more
quickly than after RABV infection. One aspect of VSV that can
be exploited in the future to ameliorate the speed of toxicity is
the use of VSV mutants and variants. One such mutant is the
M51R, which permitted us to conduct physiological analyses of
pre-and post-synaptic cells (Beier et al., 2011). We are in the
process of examining the transmission properties of this mutant
in vivo, as well as the effects of other mutations or viral variants
on prolonging the health of neurons after infection.
SUMMARY
rVSV vectors can be used to study the connectivity of neuronal
circuitry. In addition to combinations of replication-competent
forms of VSV, the replication-incompetent, monosynaptic forms
of the virus can be easily combined, without the need to change
viruses (Beier et al., 2011). This allows a straightforward way
to study both the projections into, and out from, a genetically
defined cell population. This can be done with the same viral
genome, with the only change needed being the glycoprotein, for
the selection of the direction of transmission. This flexibility of
VSV makes it a powerful, multi-application vector for studying
connectivity in the CNS.
MATERIALS AND METHODS
VIRUS CONSTRUCTION AND PRODUCTION
All rVSV clones were cloned from the rVSVG backbone
(Chandran et al., 2005). mCherry, Kusabira orange, Venus, and
CFP were cloned into the first (GFP) position using XhoI and
MscI sites, and VSV-G (a gift from Richard Mulligan, Harvard
Medical School, Boston, MA) and RABV-G (a gift from Ed
Callaway, Salk Institute, San Diego, CA) were cloned into the fifth
(G) position using the MluI and NotI restriction sites. Genes for
fluorescent proteins were obtained from Clontech.
Viruses were rescued as previously described (Whelan et al.,
1995). At 95% confluency, eight 10 cm plates of BSR cells were
infected at an MOI of 0.01. Viral supernatants were collected at
24-h time intervals and ultracentrifuged at 21,000 RPM using a
SW28 rotor and resuspended in 0.2% of the original volume. For
titering, concentrated viral stocks were applied in a dilution series
to 100% confluent BSR cells and plates were examined at 12 hpi.
Viral stocks were stored at −80◦C.
ForGviruses, 293T cells were transfected with PEI (Ehrhardt
et al., 2006) at 70% confluency on 10 cm dishes with 5µg of
pCAG-RABV-G. Twenty-four hours post-infection, the cells were
infected at an MOI of 0.01 with rVSVG expressing either GFP
or mCherry. Viral supernatants were collected for the subsequent
4 days at 24 h intervals.
Virus preparations are now available from the Salk GT3 viral
core (http://vectorcore.salk.edu/). All plasmids are available from
Addgene (http://www.addgene.org/).
AAV VECTORS
AAV-FLEx-RABV-G and AAV-FLEx-TVA-mCherry plasmids
originated from the Lab of Naoshige Uchida (Watabe-Uchida
et al., 2012), and virus stocks were generous gifts from Brad
Lowell, Harvard Medical School.
INJECTIONS OF MICE
ChAT-Cre (B6;129S6-Chattm1(cre)Lowl/J) and Ai9 (B6.Cg-
Gt(ROSA)26Sor<tm9(CAG-tdTomato)Hze>/J) mice were
obtained from the Jackson Laboratory (Madisen et al., 2010).
Eight-week-old CD-1 mice were injected using pulled cap-
illary microdispensers (Drummond Scientific, Cat. No: 5-000-
2005), using coordinates from The Mouse Brain in Stereotaxic
Coordinates (Franklin and Paxinos, 1997). Injection coordinates
(in mm) used were:
Primary Motor Cortex: A/P +1.34 from bregma, L/M 1.7,
D/V −1 from pial surface
LGN: A/P −2.46 from bregma, L/M 2, D/V −2.75
Superior Colliculus: A/P −3.88 from bregma, L/M 0.5,
D/V −1
CP: A/P +1 from bregma, L/M 1.8, D/V −2.5
Primary Visual Cortex (V1): A/P −3.4 from bregma, L/M 2.5,
D/V −0.8.
SNr: A/P −3.28 from bregma, L/M 1.5, D/V −4.25
For multi-color analysis (Figures 1C,D), 3 × 109 ffu/mL rVSV
was injected into various regions. For CP injections, 100 nL of
rVSV(RABV-G) or rVSV(VSV-G) at 3 × 107 ffu/mL was injected
at a rate of 100 nL/min. For the replication-incompetent viruses,
100 nL of 1 × 107 ffu/mL rVSVG(RABV-G) or rVSVG (VSV-
G) was injected. In the motor cortex, 100 nL of 1 × 107 ffu/mL
rVSV(RABV-G) was injected, and mice harvested 2 dpi. For
V1 injections, 100 nL of 3 × 1010 ffu/mL rVSV(RABV-G) was
injected, and mice were examined 3 or 7 dpi.
For infections of the dura mater, 1µL of 3 × 1010 ffu/mL
rVSV(RABV-G) was applied to the surface of the dura. The virus
was allowed to absorb, and the surface was subsequently covered
in bone wax, and the wound sutured.
For co-injections of virus into the same animal, 100
nL of a combination of 3 × 107 ffu/mL rVSV(VSV-G) and
3 × 108 ffu/mL rVSV(RABV-G) were co-injected into the
motor cortex, and brains examined 3 dpi. For injections of
the viruses into different regions, 100 nL of 3 × 107 ffu/mL
rVSV(VSV-G) was injected into M1, and 100 nL of 3 × 108
ffu/mL rVSV(RABV-G) into the SNr, and brains examined 3 dpi.
A lower titer of rVSV(VSV-G) was used, as rVSV(RABV-G) is
attenuated.
All mouse work was conducted in biosafety containment
level 2 conditions and was approved by the Longwood Medical
Area Institutional Animal Care and Use Committee.
SLICE PREPARATION AND PHARMACOLOGY
Recordings were made from cortical pyramidal neurons in
slices taken from postnatal day 12–18 mice, inoculated in
the CP 12–18 h prior with rVSV(RABV-G). Coronal slices
(300µm thick) were cut in ice-cold external solution con-
taining (in mM): 110 choline, 25 NaHCO3, 1.25 NaH2PO4,
2.5 KCl, 7 MgCl2, 0.5 CaCl2, 25 glucose, 11.6 Na-ascorbate,
and 3.1 Na-pyruvate, bubbled with 95% O2 and 5% CO2.
Slices were then transferred to artificial cerebrospinal fluid
(ACSF) containing (in mM): 127 NaCl, 25 NaHCO3, 1.25
NaH2PO4, 2.5 KCl, 1 MgCl2, 2 CaCl2, and 25 glucose, bub-
bled with 95% O2 and 5% CO2. After an incubation period
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of 30–40min at 34◦C, slices were stored at room tempera-
ture. All experiments were conducted at room temperature
(25◦C). In all experiments, 50µM picrotoxin, 10µM 2,3-Dioxo-
6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline -7-sulfonamide
(NBQX), and 10µM 3-((R)-2-Carboxypiperazin-4-yl)-propyl-
1-phosphonic acid (CPP) were present in the ACSF to block
GABAA/C, AMPA, and NMDA receptor-mediated transmission,
respectively. All chemicals were from Sigma or Tocris.
ELECTROPHYSIOLOGY AND IMAGING
Whole-cell recordings were obtained from infected and unin-
fected deep layer cortical pyramidal neurons identified with
video-IR/DIC and GFP fluorescence was detected using epi-
fluorescence illumination. With the deep layers of the cortex,
2-photon laser scanning microscopy (2PLSM) was used to con-
firm the cell types based on morphology. Deep layer pyramidal
neurons had large cell bodies, classic pyramidal shape and den-
dritic spines. Glass electrodes (2–4 M) were filled with internal
solution containing (in mM): 135 KMeSO4, 5 KCl, 5 HEPES,
4 MgATP, 0.3 NaGTP, 10 Na2HPO4, 1 EGTA, and 0.01 Alexa
Fluor-594 (to image neuronal morphology) adjusted to pH 7.4
with KOH. Current and voltage recordings were made at room
temperature using a AxoPatch 200B or a Multiclamp 700B ampli-
fier. Data was filtered at 5 kHz and digitized at 10 kHz.
DATA ACQUISITION AND ANALYSIS
Imaging and physiology data were acquired and analyzed as
described previously (Carter and Sabatini, 2004). Resting mem-
brane potential was determined by the average of three 5-s sweeps
with no injected current. Passive properties of the cell, membrane
(Rm) and series resistance (Rs) and capacitance (Cm), were mea-
sured while clamping cells at −65mV and applying voltage steps
from−55 to −75mV. The current—firing relationship was deter-
mined in current clamp with 1-s periods of injected current from
100 to 500 pA.
HIPPOCAMPAL SLICE CULTURES
The time course of viral gene expression experiments were car-
ried out in organotypic hippocampal slice cultures prepared from
postnatal day 5–7 Sprague-Dawley rats as described previously
(Stoppini et al., 1991). Slices were infected after 7 days in vitro,
and images were acquired on a two-photon microscope.
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